Rejensa for Dogs: Does It Really Work? What the Data Shows

by

Rejensa for Dogs: Does It Really Work? What the Data Shows

Rejensa is a prescription-adjacent joint chew sold through veterinarians that contains N-Butyryl Glucosamine (branded Gluco Blu), a lab-modified version of glucosamine rather than the glucosamine hydrochloride or sulfate found in most drugstore joint supplements. The manufacturer’s own dog study found it improved orthopedic exam scores and functional quality-of-life scores over 16 days, performing better than a leading glucosamine-chondroitin product in that same trial. It did not, however, match carprofen (a prescription NSAID) on the trial’s primary overall pain measure. Whether it’s worth the price tag depends on what you’re comparing it to and what you actually need it to do.

Answer Box: Rejensa in 30 Seconds

  • Active ingredient: N-Butyryl Glucosamine (Gluco Blu), 1,620 mg per chew
  • Sold by: Phibro Animal Health, through veterinary clinics and veterinary-authorized retailers (not general pet stores)
  • Evidence: One sponsor-funded, unpublished 24-dog crossover study (CanCog Technologies, 2018) plus older in vitro and rat-model research on the molecule itself
  • What it beat: A “leading glucosamine chondroitin sulphate” product on orthopedic exam scores and QOL function scores
  • What it didn’t beat: Carprofen, on the study’s primary overall QOL score
  • Cost: Premium-tier, comparable to or higher than veterinary-exclusive joint chews like Dasuquin
  • Best fit: Dogs with early-to-moderate osteoarthritis whose owner wants a vet-dispensed option and is comfortable with the current evidence base

What Is Rejensa, Exactly?

Rejensa is manufactured by Phibro Animal Health (the product was originally developed by Aratana Therapeutics, later folded into Elanco’s animal health portfolio before its current ownership). Each chew delivers 1,620 mg of N-Butyryl Glucosamine per the product label filed with Drugs.com’s veterinary database, dosed by the dog’s weight: half a chew for dogs up to 29 lbs, a full chew for 30-59 lbs, one and a half chews for 60-89 lbs, and two chews for 90-120 lbs, given once daily.

The ingredient itself, GlcNBu, is a synthetic analog of glucosamine — chemists attached a butyryl group to the glucosamine molecule, which changes how it’s absorbed and metabolized compared to plain glucosamine HCl or sulfate. This isn’t a new discovery dressed up in marketing language; the modification has been studied in laboratory cartilage models since at least the early 2000s. A cell-culture study published in the Journal of Pharmacology and Experimental Therapeutics found that N-butyrylated glucosamine increased matrix gene expression in chondrocytes (cartilage-producing cells) more effectively than standard N-acetylglucosamine did (Bassleer et al., 2004, PMID: 15240824). A separate study in a rat model of induced arthritis found disease-modifying effects from the same compound (PMID: 17309122). Both of these are legitimate, searchable studies — but neither one is a clinical trial in dogs, and neither proves that a chew delivering 1,620 mg produces the same effect in a living, arthritic dog’s joint that it produced in a petri dish or a rat.

Does Rejensa Actually Work? What the Dog Study Found

The manufacturer’s central evidence piece is a study run by CanCog Technologies (Study #VRI163-18018-CE), using 24 Beagle dogs with radiographically confirmed osteoarthritis in at least two joints. It’s a genuinely well-designed study for what it is: a blinded, three-arm crossover trial comparing GlcNBu (dosed at 60 mg/kg), carprofen (an NSAID, dosed at 4.4 mg/kg), and a “leading glucosamine chondroitin sulphate” product, with a 10-day washout between arms.

Here’s what it actually found, not the marketing summary of it:

Measure Carprofen GlcNBu (Rejensa’s compound) Standard glucosamine/chondroitin
Overall QOL score (primary measure) Significant improvement No significant improvement No significant improvement
QOL “function” subscore Significant improvement Significant improvement No significant improvement
QOL “pain” subscore No significant improvement No significant improvement No significant improvement
Orthopedic exam score Marginally significant Significant improvement No significant improvement
T-Maze running speed / home-cage activity No effect No effect No effect

So the accurate summary is: GlcNBu outperformed the comparison glucosamine-chondroitin product on two of five measures and matched or edged out carprofen on the orthopedic exam specifically — but it did not beat carprofen on the study’s main quality-of-life score, and neither product improved measured pain scores or activity levels. That’s a real, moderate signal, not proof of dramatic pain relief.

Two important caveats belong in any honest write-up. First, this study has not been published in a peer-reviewed veterinary journal — it exists as a company-commissioned summary report, which means it hasn’t gone through independent peer review or replication. Second, it was funded by the company that sells the product, which doesn’t make the data false, but it does mean it should be weighed the way any single-source industry study is weighed: as supportive evidence, not as the final word. Reputable sources like the Merck Veterinary Manual note broadly that nutraceutical joint compounds “may provide symptomatic relief” but that evidence quality varies widely by product and ingredient.

N-Butyryl Glucosamine vs. Standard Glucosamine

Factor Standard Glucosamine (HCl/sulfate) N-Butyryl Glucosamine (Rejensa)
Chemical form Naturally occurring amino sugar Lab-synthesized glucosamine analog
Typical chew dose Often 250-600 mg per chew 1,620 mg per chew
In vitro cartilage-gene evidence Established, decades of data Positive signal in one cell study (2004)
Dog-specific clinical data Multiple published trials over 20+ years, mixed results One unpublished 24-dog company study (2018)
Distribution OTC, pet stores, online Veterinary-dispensed only
Regulatory evidence bar Marketed as a supplement Marketed as a supplement (not FDA-approved as a drug)

The dosage difference is real and verifiable from the product label — 1,620 mg of GlcNBu is a meaningfully larger number than what most OTC chews list for standard glucosamine. But because GlcNBu is a different molecule with different pharmacokinetics, that number isn’t directly comparable milligram-for-milligram to glucosamine HCl; a bigger number on a different compound isn’t automatically a bigger clinical effect. Research suggests the modified form may be handled differently by the body, but dog-specific absorption and bioavailability data comparing the two head-to-head in a controlled pharmacokinetic study haven’t been published as of this writing.

For a broader look at how standard glucosamine performs across the research base, see our glucosamine for dogs guide, and for how the major joint-chew categories stack up against each other, our best joint supplement for dogs comparison is a useful next read.

Rejensa vs. Dasuquin and Other Vet-Exclusive Chews

Rejensa competes most directly with other veterinary-channel joint products rather than with grocery-aisle supplements. If your vet has recommended Rejensa, it’s worth knowing how it’s positioned relative to the other name most vets mention in the same breath.

Dasuquin (glucosamine HCl, chondroitin sulfate, and ASU) has a considerably larger published evidence base behind its core ingredients, spanning multiple peer-reviewed canine studies over two decades, though individual-product trials specifically on the Dasuquin formulation are more limited. Our Dasuquin vs. Cosequin comparison breaks down how those two long-standing products differ, and our Dasuquin Advanced review covers the newer MSM-added formulation in more depth. Rejensa’s pitch is a novel mechanism and a faster reported onset (as little as 16 days in the company’s trial), traded against a much thinner independent evidence trail.

A Buyer’s Decision Framework

Use this as a rough filter, not a diagnosis:

  • Your dog has mild, early joint stiffness and no diagnosed osteoarthritis — a standard OTC glucosamine/chondroitin chew is a reasonable, well-evidenced starting point. See our dog joint pain relief guide for a fuller rundown of non-drug options.
  • Your vet has diagnosed osteoarthritis and wants to try a nutraceutical before or alongside an NSAID — Rejensa is a reasonable candidate precisely because it’s vet-dispensed and vet-monitored, and the available (if limited) data shows some functional benefit.
  • Your dog needs meaningful pain control now — the CanCog data itself shows carprofen outperformed GlcNBu on the primary pain measure. A supplement, including Rejensa, is not a substitute for prescribed pain management in a dog that’s actively suffering.
  • Budget is the deciding factor — Rejensa sits at a premium price point similar to other veterinary-exclusive chews; a standard glucosamine/chondroitin product will cost meaningfully less with a broader (if more mixed) research record behind its ingredients.

What to Realistically Expect, Week by Week

Company trial data measured effects over a 16-day treatment arm, so “week by week” expectations beyond that window are extrapolated, not directly studied:

  • Days 1-7: No noticeable change is typical. Joint supplements of any kind are not fast-acting like an NSAID.
  • Days 10-16: This is the window in which the CanCog study detected statistically significant improvement in orthopedic exam scores and QOL function scores. Owners may or may not notice a subjective difference at home; the study’s own activity monitors (Actical devices) did not detect a measurable change in home-cage activity even when exam scores improved.
  • Weeks 4-8: If a response hasn’t emerged by this point, most veterinary guidance on joint nutraceuticals generally suggests reassessing the plan rather than continuing indefinitely on faith.
  • Ongoing: Joint supplements, including Rejensa, are maintenance products. They’re not expected to reverse existing cartilage damage.

Myth vs. Fact

Myth: “Rejensa is a prescription drug.”
Fact: It’s regulated and marketed as an animal health supplement/nutraceutical dispensed through veterinary channels, not an FDA-approved prescription drug.

Myth: “The clinical study proves Rejensa relieves pain as well as an NSAID.”
Fact: The company’s own study found carprofen — not Rejensa — produced the only statistically significant improvement on the overall quality-of-life score, which was the study’s primary pain-and-function measure.

Myth: “Because the dose is higher (1,620 mg), it must work better than regular glucosamine.”
Fact: GlcNBu and glucosamine HCl/sulfate are different molecules, so their doses aren’t directly comparable milligram-for-milligram. A larger number on the label doesn’t by itself indicate a larger clinical effect.

Myth: “If it’s sold by a vet, it must have gone through the same review as a drug.”
Fact: Veterinary-exclusive distribution reflects the manufacturer’s sales channel and clinical positioning, not FDA drug approval. Animal supplements are not required to prove efficacy before sale the way prescription drugs are.

When to Call Your Vet Instead of Reaching for a Supplement

Contact your veterinarian promptly, rather than starting or continuing any joint supplement, if your dog shows:

  • Sudden inability or reluctance to bear weight on a limb
  • Visible joint swelling, heat, or pain on gentle palpation
  • Rapid worsening of stiffness over days rather than months
  • Signs of pain at rest, not just after activity (panting, restlessness, guarding a limb)
  • No improvement after 6-8 weeks of consistent supplement use
  • Any existing NSAID or prescription medication, since your vet should confirm there’s no interaction before adding a new joint product

A joint supplement — Rejensa or otherwise — is a maintenance and support tool. It is not designed to diagnose, treat, or replace veterinary evaluation of a dog in pain.

Home-based supportive strategies — weight management, low-impact exercise, and environmental modifications — pair well with any supplement plan and have their own independent evidence behind them.

Where a Standard Chew Might Fit

Joint support isn’t only about which molecule sits on the label. For owners whose dog has mild stiffness that hasn’t been diagnosed as osteoarthritis — or who are looking for a lower-cost daily-maintenance option to use once a vet has ruled out anything requiring Rejensa-level intervention — a hip and joint chew formulated for everyday support can be a reasonable complement. It shouldn’t be treated as a substitute for veterinary diagnosis in a dog with confirmed joint disease.

FAQ

Is Rejensa the same as regular glucosamine?
No. Rejensa’s active ingredient is N-Butyryl Glucosamine (Gluco Blu), a lab-modified analog of glucosamine, not the glucosamine hydrochloride or sulfate used in most over-the-counter joint chews.

Do you need a prescription for Rejensa?
Rejensa isn’t a prescription drug, but it’s distributed exclusively through veterinary clinics and veterinary-authorized retailers rather than general pet stores, so in practice you’ll usually get it through or with input from your vet.

How fast does Rejensa work?
The manufacturer’s own study measured statistically significant improvement in orthopedic exam and function scores within a 16-day treatment period. Individual results vary, and the same study found no measurable change in the dogs’ actual home-cage activity levels during that window.

Is there independent, peer-reviewed research on Rejensa specifically?
The core canine trial (CanCog Technologies, 24 Beagles) is a company-commissioned study that has not been published in a peer-reviewed journal. Earlier laboratory research on the GlcNBu molecule itself has appeared in peer-reviewed sources, including a 2004 cartilage cell-culture study and a 2007 rat arthritis model study, but neither of those is a dog clinical trial.

Can Rejensa be given with an NSAID like carprofen?
The product label states it may be used alongside prescribed joint medications or as a standalone supplement, but any combination should be confirmed with your veterinarian, since they can assess your dog’s specific health history.

Is Rejensa worth the price compared to Dasuquin or Cosequin?
That depends on your priorities. Rejensa offers a novel mechanism and a vet-dispensed, vet-monitored positioning, but Dasuquin’s core ingredients have a much longer independent research trail. Neither has definitively “won” head-to-head in independent, peer-reviewed dog trials.

References

Veterinary Disclaimer

This article is for general informational purposes only and is not a substitute for professional veterinary diagnosis, advice, or treatment. Joint supplement needs vary by dog, and any decision to start, stop, or combine a joint product with medication should be made in consultation with your veterinarian, who can evaluate your dog’s specific health history and current condition.

Leave a Comment